A Retrospective Multicenter Cohort Study Assessing Belimumab Effects on Disease Activity, Damage progression, Remission and Low Disease Activity
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- Acronyms BeRLiSS
- 04 Jun 2022 Results assessing rates and predictors of CLASI50 and CLASI70 in the Berliss multicentric SLE cohort 1 of patients treated with belimumab presented at the 23rd Annual Congress of the European League Against Rheumatism
- 14 Apr 2020 New trial record
- 10 Apr 2020 Results published in the Arthritis and Rheumatology